Differing sensitivity of tumor cells to apoptosis induced by iron deprivation in vitro

Cell and Tissue Models

Summary

We studied the sensitivity of tumor cells to the induction of apoptosis by iron deprivation. Iron deprivation was achieved by the employment of a defined iron-deficient culture medium. Mouse 38C13 cells and human Raji cells die within 48 and 96 h of incubation in iron-deficient medium, respectively. On the contrary, mouse EL4 cells and human HeLa cells are completely resistant to the induction of death under the same experimental arrangement. Deoxyribonucleic acid fragmentation analysis by agarose gel electrophoresis as well as flow cytometric analysis after propidium iodide staining detected in 38C13 and Raji cells, but not in EL4 and HeLa cells, changes characteristic to apoptosis. The 38C13 cells, sensitive to iron deprivation, also displayed a similar degree of sensitivity to apoptosis induction by thiol deprivation (achieved by 2-mercaptoethanol withdrawal from the culture medium) as well as by rotenone (50 nM), hydroxyurea (50 μM), methotrexate (20 nM), and doxorubicin (100 nM). Raji cells shared with 38C13 cells a sensitivity to rotenone, methotrexate, doxorubicin, and, to a certain degree, to hydroxyurea. However, Raji cells were completely resistant to thiol deprivation. EL4 and HeLa cells, resistant to iron deprivation, also displayed a greater degree of resistance to most of the other apoptotic stimuli than did their sensitive counterparts. We conclude that some tumor cells in vitro are sensitive to apoptosis induction by iron deprivation, while other tumor cells are resistant. All the tumors found to be sensitive to iron deprivation in this study (four cell lines) are of hematopoietic origin. The mechanism of resistance to apoptosis induction by iron deprivation differs from the mechanism of resistance to thiol deprivation.

Key words

sensitivity to apoptosis apoptosis induction iron deprivation tumor cell lines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brooks, D.; Taylor, C.; Dos Santos, B.; Linden, H.; Houghton, A.; Hecht, T.; Kornfeld, S.; Taetle, R. Phase Ia trial of murine IgA anti-transferrin receptor antibody 42/6. Clin. Cancer Res. 1:1259–1265; 1995.PubMedGoogle Scholar
  2. Chen, T. R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp. Cell Res. 104:255–262; 1977.PubMedCrossRefGoogle Scholar
  3. Chitambar, C. R.; Boom, P.; Wereley, J. P. Evaluation of transferrin and gallium-pyridoxal isoicotinoyl hydrazone as potential therapeutic agents to overcome lymphoid leukemic cell resistance to gallium nitrate. Clin. Cancer Res. 2:1009–1015; 1999.Google Scholar
  4. Donfrancesco, A.; Deb, G.; Angioni, A., et al. D-CECaT: a breakthrough for patients with neuroblastoma. Anticancer Drugs 4:317–321; 1993.PubMedCrossRefGoogle Scholar
  5. Donfrancesco, A.; Deb, G.; De Sio, L.; Cozza, R.; Castellano, A. Role of deferoxamine in tumor therapy. Acta Haematol. 95:66–69; 1996.PubMedGoogle Scholar
  6. Donfrancesco, A.; Deb, G.; Dominici, C.; Pileggi, D.; Castello, M. A.; Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. 50:4929–4930; 1990.PubMedGoogle Scholar
  7. Fukuchi, K.; Tomoyasu, S.; Tsuruoka, N.; Gomi, K. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett. 350:139–142; 1994.PubMedCrossRefGoogle Scholar
  8. Fukuchi, K.; Tomoyasu, S.; Watanabe, H.; Kaetsu, S.; Tsuruoka, N.; Gomi, K. Iron deprivation results in an increase in p53 expression. Biol. Chem. Hoppe-Seyler 376:627–630; 1995.PubMedGoogle Scholar
  9. Head, J. F.; Wang, F.; Elliott, R. L. Antineoplastic drugs that interfere with iron metabolism in cancer cells. Adv. Enzyme Regul. 37:147–169; 1997.PubMedCrossRefGoogle Scholar
  10. Hileti, D.; Panayiotidis, P.; Hoffbrand, A. V. Iron chelators induce apoptosis in proliferating cells. Br. J. Haematol. 89:181–187; 1995.PubMedGoogle Scholar
  11. Hoffman, B.; Liebermann, D. A. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive & negative modulators. Oncogene 9:1807–1812; 1994.PubMedGoogle Scholar
  12. Hsieh-Ma, S. T.; Shi, T.; Reeder, J.; Ring, D. B. In vitro tumor growth inhibition by bispecific antibodies to human transferrin receptor and tumor-associated antigens is augmented by the iron chelator deferoxamine. Clin. Immunol. Immunopathol. 80:185–193; 1996.PubMedCrossRefGoogle Scholar
  13. Ido, Y.; Muto, N.; Inada, A., et al. Induction of apoptosis by hinokitiol, a potent iron chelator, in teratocarcinoma F9 cells is mediated through the activation of caspase-3. Cell Prolif. 32:63–73; 1999.PubMedGoogle Scholar
  14. Jacobson, M. D.; Weil, M.; Raff, M. C. Programmed cell death in animal development. Cell 88:347–354; 1997.PubMedCrossRefGoogle Scholar
  15. Kemp, J. D. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transferrin receptor. Histol. Histopathol. 12:291–296; 1997.PubMedGoogle Scholar
  16. Kemp, J. D.; Cardillo, T.; Stewart, B. C.; Kehrberg, E.; Weiner, G.; Hedlund, B.; Naumann, P. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate sand IgG monoclonal antibodies against the transferrin receptor. Cancer Res. 55:3817–3824; 1995.PubMedGoogle Scholar
  17. Kemp, J. D.; Thorson, J. A.; Stewart, B. C.; Naumann, P. W. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and IgG monoclonal antibody against the transferrin receptor. Evidence for a threshold model of iron deprivation toxicity. Cancer Res. 52:4144–4148; 1992.PubMedGoogle Scholar
  18. Kontouras, J.; Boura, P.; Karolides, A.; Zaharioudaki, E.; Tsapas, G. Recombinant α2 interferon (α-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma. Hepatogastroenterology 42:31–36; 1995.Google Scholar
  19. Kovář, J. Growth-stimulating effect of ferric citrate on hybridoma cells: characterization and relation to transferrin function. Hybridoma 7:255–263; 1988.PubMedGoogle Scholar
  20. Kovář, J.; Franěk, F. Iron compounds at high concentrations enable hybridoma growth in a protein-free medium. Biotechnol. Lett. 9:259–265; 1987.CrossRefGoogle Scholar
  21. Kovář, J.; Franěk, F. Growth-stimulating effect of transferrin on a hybridoma cell line: relation to transferrin iron-transporting function. Exp. Cell Res. 182:358–369; 1989.PubMedCrossRefGoogle Scholar
  22. Kovář, J.; Naumann, P. W.; Stewart, B. C.; Kemp, J. D. Differing sensitivity of non-hematopoietic human tumors to synergistic anti-transferrin receptor monoclonal antibodies and deferoxamine in vitro. Pathobiology 63:65–70; 1995.PubMedGoogle Scholar
  23. Kovář, J.; Seligman, P.; Gelfand, E. W. Differential growth-inhibitory effects of gallium on B-lymphocyte lines in high versus low iron concentrations. Cancer Res. 50:5727–5730; 1990.PubMedGoogle Scholar
  24. Kovář, J.; Stunz, L. L.; Stewart, B. C.; Kriegerbeckova, K.; Ashman, R. F.; Kemp, J. D. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Pathobiology 65:61–68; 1997.PubMedCrossRefGoogle Scholar
  25. Leardi, A.; Caraglia, M.; Selleri, C., et al. Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells. Br. J. Haematol. 102:746–752; 1998.PubMedCrossRefGoogle Scholar
  26. Porter, J. B.; Lynagh, G. R.; Hider, R. C. Iron chelators promote apoptosis in thymocytes and proliferating leukaemia cells. Br. J. Haematol. 87 (Suppl. 1):114; 1994.Google Scholar
  27. Raff, M. Cell suicide for beginners. Nature 396:119–122; 1998.PubMedCrossRefGoogle Scholar
  28. Riaz-Ul-Haq; Werely, J. P.; Chitambar, C. R. Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp. Hematol. 23: 428–432; 1995.Google Scholar
  29. Seidman, A. D.; Scher, H. I.; Heinemann, M. H.; Bajorin, D. F.; Sternberg, C. N.; Dershaw, D. D.; Silverberg, M.; Bosl, G. J. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68:2561–2565; 1991.PubMedCrossRefGoogle Scholar
  30. Seligman, P. A.; Crawford, E. D. Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J. Natl. Cancer Inst. 83:1582–1584; 1991.PubMedCrossRefGoogle Scholar
  31. Taetle, R.; Honeysett, J. M.; Bergeron, R. Combination iron depletion therapy. J. Natl. Cancer Inst. 81:1229–1235; 1989.PubMedCrossRefGoogle Scholar
  32. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456–1462; 1995.PubMedCrossRefGoogle Scholar
  33. Weiner, R. E.; Avis, I.; Neumann, R. D.; Mulshine, J. L. Transferrin dependence of Ga(NO3)3 inhibition of growth in human-derived small cell lung cancer cells. J. Cell. Biochem. 24(Suppl.):276–287; 1996.CrossRefGoogle Scholar
  34. White, S.; Taetle, R.; Seligman, P. A.; Rutherford, M.; Trowbridge, I. S. Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res. 50:6295–6301; 1990.PubMedGoogle Scholar

Copyright information

© Society for In Vitro Biology 2001

Authors and Affiliations

  • Jan Kovář
    • 1
  • Tomáš Valenta
    • 1
  • Hana Štýbrová
    • 1
  1. 1.Institute of Molecular GeneticsAcademy of Sciences of the Czech RepublicPrague 4Czech Republic

Personalised recommendations